Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/6/2008

ROCKVILLE, Md., March 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three months and twelve months ended December 31, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

For fiscal year 2007, revenues were $7.4 million versus $6.9 million for 2006. For the year ended December 31, 2007, the Company reported a net loss of ($23.4 million) or ($0.28) per share, versus ($50.9 million), or ($0.71) per share, for fiscal year 2006. As of December 31, 2007, the Company had cash and short-term investments of approximately $47.7 million.

Revenues for the fourth quarters ended December 31, 2007 and December 31, 2006 were both $3.9 million. The Company reported a net loss of ($4.0 million), or ($.05) per share for the three months ended December 31, 2007. This compares with a net loss of ($5.9 million), or ($0.08) per share for the fourth quarter 2006.

Dane R. Saglio, EntreMed Chief Financial Officer, commented, "Financial results for 2007 reflect an increase in both revenue and research and development expenses versus 2006. For the year, we recorded $7.4 million in royalty revenue, a small increase over 2006 royalty revenues of $6.9 million. While research and development expenses decreased in the fourth quarter, there was an increase of approximately $2 million for the full year as a result of the initiation of multiple Phase 2 trials for MKC-1 and Panzem(R) NCD, as well as the submission and acceptance of two IND filings in 2007. In addition to reporting our opera
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ANGHAI,Nov.24/PRNewswire-Asia/--ShanghaiBiolaxyann...SFDA)hasapprovedthe,investigationalnewdrugapplicat...tiveinsulinformulationtotreatdiabetes.ThisIND,appr...tudy. , Diabetesisadisordercharacteristicofhi...fdiabetesoftenresultinseveremicro-and,macro-vascul...
(Date:11/24/2009)... The FBI recently approved the Prom... participating in or generating DNA records for th... Madison, WI USA (PRWEB) -- The FBI recently ... for use by laboratories participating in, or gene...tem (NDIS). NDIS currently contains more than seve...
(Date:11/24/2009)...XVENTURE:HTL , TORONTO,Nov.24/PRNewswire-Firs...toCapitalInc.,aleadingproviderofadvancedlasersyste...clinicmarkets,todayreportedoperationalandfinancial... ,Q32009Highlights,-Revenuewas$1.46millioncompare...3percentcomparedwith66.1percentinQ3,2008,-Netlossr...
(Date:11/24/2009)...NDIEGO,Nov.24,2009/PRNewswire-FirstCall/--ArenaPha...atthecompanyisscheduledtopresentatthePiperJaffray2...30a.m.EasternTime(8:30a.m.PacificTime)attheNewYork...t andChiefExecutiveOfficer,isscheduledtoprovideano...tanddiscoveryprograms. ,, Aliveaudiowebcastofth...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...estructuring Gov. Jim Doyle has signed the Wiscons...the Biomedical Technology Alliance . , ,In the fi...rtial veto on a proposed grant of $2.5 million to ... and investors located in southeastern Wisconsin. ... providing the organization with $500,000. , ,The ...
...ing in Philadelphia last month, the globalization ...really taken flight. The company that perhaps best... in its annual report on biotechnology. , ,This re...al BIO meeting. This years report, which carries t...hnology Report 2005, is a treasure lode of data fo...
...gned into law Monday by Gov. Jim Doyle will sharpe...y firms by changing how corporate income from out-...in Technology Council. , ,With bipartisan support...o extend the "single-sales factor" sales apportion...e firms in Wisconsin. Two years ago, the state beg...
Other Biology Technology:Doyle partially vetoes SE Wisconsin technology grant 2Doyle partially vetoes SE Wisconsin technology grant 3Globalization of biotech industry is a decidedly worldwide phenomenon 2Globalization of biotech industry is a decidedly worldwide phenomenon 3`Single-sales factor' extends tax treatment to tech, service firms 2`Single-sales factor' extends tax treatment to tech, service firms 3
(Date:11/25/2009)... firefighters, police officers and ambulance worke...rade Center complex. They battled to save people f...vors, tackled fires and evacuated as many people a...ed 17,000 people. And making their jobs even harde...ed workers and their relatives jammed mobile netwo...
(Date:11/25/2009)...EMBER 25, 2009 Soil is the linchpin of the enviro...e meet. Despite that, many students see soil as "j...e. Soil science educators are challenged with the ...the critical importance of soil in the environment... earth science teachers at University of Nebraska-...
(Date:11/25/2009)...niversity assistant professors recently received f...to continue research beneficial to understanding t..., Christopher Blackwood, assistant professor in t...grants to support two separate research projects. ...ecomposer Communities and Functions from the Leaf ...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3It's not just dirt! 2Kent State University professors focus research on the environment with grants totaling $890,000 2Pinhead size worms + robot 3D new antibiotics 9481 1The Reduction of Eye Fatigue Improves Vision in Older Subjects 53740 1The Reduction of Eye Fatigue Improves Vision in Older Subjects 53740 2Multi state Medicare Fraud Crackdown Focuses Attention on Recovery Payoffs to Defray Health Reform Costs 53738 1Multi state Medicare Fraud Crackdown Focuses Attention on Recovery Payoffs to Defray Health Reform Costs 53738 2
...cialists (CSS),announces two additions to its Rese... hired Randy Biela, a software engineer, and David....newscom.com/cgi-bin/prnh/20070119/CGF030LOGO ) E..., "we now have an,R&D department of five full-time... largest R&D team in the industry and rivals the R...
...te., The record holder in the Pacific Northwest, ... Clearwater River, Idaho, in April 2003. A year an...il Islands near Japan. The most direct route betwe...y is 4,200 miles. Imagine fish that make it that ... streams in order to spawn., The ability of salmo...
...educes illness severity and duration in children o... hours of symptom onset, according to new data pre...us Disease (WISPID) meeting in Bangkok 15-18 Novem...e the incidence of respiratory tract infections, e... season smaller child sized Tamiflu (oseltamivir) ...
Other Biology News:Corporate Safe Specialists Announces Additions to R&D Team 2UW launches cutting-edge DNA 'fin-printing' project for salmon 2UW launches cutting-edge DNA 'fin-printing' project for salmon 3Tamiflu effective for treatment and prevention of influenza in children 1 year and older 2Tamiflu effective for treatment and prevention of influenza in children 1 year and older 3
SYBR Safe photographic filter from Molecular Probes (Invitrogen)
Rat Complement from Pel-Freez Biologicals
bacterial endotoxin Chromogenic Assay Kit from Cell Sciences
Rabbit Anti-Human UCP2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Biology Products: